Li Wenman, Chen Xiaoming, Chen Sijie, Lv Zhiqing, Tang Jing, Li Ni
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Cutan Ocul Toxicol. 2025 Mar;44(1):35-42. doi: 10.1080/15569527.2024.2431570. Epub 2024 Dec 2.
In this study, we aimed to investigate the incidence of objective and subjective indicators of the prostaglandin-associated periorbital syndrome (PAPS) after continuous instillation of topical prostaglandin analogues (PGAs) in primary open-angle glaucoma or ocular hypertension patients.
A self-controlled and prospective study of PGA instillation was performed in patients ( = 55) with primary open-angle glaucoma or ocular hypertension. Bilateral instillation of bimatoprost, travoprost, latanoprost, or tafluprost was conducted (treatment, 3-6 months). The objective indicators recorded included interpupillary distance (IPD) and exophthalmos; subjective indicators were assessed via colour pictures of the periocular area. Data from before the administration of medication served as controls. Posttreatment changes in IPD, exophthalmos, deepening of the upper eyelid sulcus, periorbital hyperpigmentation and eyelash growth were analysed.
Compared with those before treatment, the interpupillary distance (IPD) differed from the baseline value at 1 month after treatment ( < 0.0001), and the exophthalmos only significantly differed from the baseline value at month 3 ( = 0.0005). Visible periorbital changes at 1, 3, and 6 months after treatment were assessed, and the incidence of eyelash growth and thickening was 7.27%, 45.45% and 66.67%, respectively. The incidence of periorbital hyperpigmentation was 7.2%, 18.18% and 33.33%, respectively. The incidence of upper-eyelid sulcus deepening was 3.64%, 7.27% and 16.27%, respectively. Bimatoprost had the highest incidence of PAPS, followed by travoprost and tafluprost, and latanoprost had the lowest incidence after three months of treatment in the between-group comparison.
As an objective index to evaluate PAPS, the change of IPD was more obvious than the exophthalmos. Visible periorbital changes gradually appeared after three months of medication. Bimatoprost caused the most severe PAPS, and latanoprost caused the least severe PAPS.
The study was registered at www.chictr.org.cn on 15 April 2021, under the identifier ChiCTR2100045465.
在本研究中，我们旨在调查原发性开角型青光眼或高眼压症患者连续滴用局部前列腺素类似物（PGA）后前列腺素相关眶周综合征（PAPS）的客观和主观指标发生率。
对55例原发性开角型青光眼或高眼压症患者进行了一项关于PGA滴用的自我对照前瞻性研究。双侧滴用比马前列素、曲伏前列素、拉坦前列素或他氟前列素（治疗3 - 6个月）。记录的客观指标包括瞳孔间距（IPD）和眼球突出度；主观指标通过眼周区域的彩色图片进行评估。用药前的数据作为对照。分析治疗后IPD、眼球突出度、上睑沟加深、眶周色素沉着和睫毛生长的变化。
与治疗前相比，治疗后1个月时瞳孔间距（IPD）与基线值不同（<0.0001），眼球突出度仅在第3个月时与基线值有显著差异（=0.0005）。评估了治疗后1、3和6个月时可见的眶周变化，睫毛生长和变粗的发生率分别为7.27%、45.45%和66.67%。眶周色素沉着的发生率分别为7.2%、18.18%和33.33%。上睑沟加深的发生率分别为3.64%、7.27%和16.27%。在组间比较中，治疗3个月后，比马前列素的PAPS发生率最高，其次是曲伏前列素和他氟前列素，拉坦前列素的发生率最低。
作为评估PAPS的客观指标，IPD的变化比眼球突出度更明显。用药3个月后可见眶周变化逐渐出现。比马前列素引起的PAPS最严重，拉坦前列素引起的PAPS最轻。
该研究于2021年4月15日在www.chictr.org.cn注册，标识符为ChiCTR2100045465。
